Ajax Health launches new pulsed-field ablation company called Cortex

Ajax Health announced today that it formed and provided funding for Cortex, a new developer of ablation technology for treating AFib.

Cortex launches with $90 million in funding commitments, led by KKR and Hellman & Friedman. AI Life Sciences and other investors also participated in this initial funding. KKR and H&F invested through the Cordis Accelerator, Cordis-X.

The new company brings together expert teams with complementary innovations in electrophysiology, according to a news release. It aims to accelerate the development and clinical validation of next-generation ablation solutions and AFib mapping technology.

The technology coming out of Cortex will be diagnostic and pulsed-field ablation (PFA) catheters. Ablacon’s Electrographic Flow mapping technology will provide comprehensive mapping and navigation capabilities. This mapping helps detect AFib sources, supporting personalized ablation therapy to potentially improve outcomes.

Read more
  • 0

DTW Podcast: Geoff Martha updates Medtronic’s new course; AJAX CEO Duke Rohlen is funding innovation differently

Medtronic CEO Geoff Martha and Ajax CEO Duke Rohlen share insights and wisdom on this episode of the podcast.

Less than a year into his role as CEO, Geoff Martha and the Medtronic leadership has overseen a significant reorganization of medtech’s largest player.

In our closing keynote conversation, Martha says the company is clearing a minor COVID-19 bump and sees open road for the company to continue to grab share from competitors.

Martha details what products are gaining the most traction while also identifying those that still have some ground to gain.

We also discuss: When it may bring its renal denervation project to the FDA Why Hugo the surgical robot will be worth the wait (and why development has taken more than a decade) Whether or not Medtronic will collaborate more with private equity firms, early-stage incubators and maybe even SPACs? What will the company’s acquisition strategy look like in 2021. And why. Why the price-cutting for drug-eluting …
Read more
  • 0

How do medtech investors, CEOs manage portfolio companies going forward?

DeviceTalks Weekly

In Episode 10 of DeviceTalks Weekly, we talk with two successful starters of medtech companies about how they’re building and maintaining their medtech portfolios during this pandemic landscape.

Our guests this week are Dr. Justin Klein, managing partner of Vensana Capital, and Duke Rohlen, chair of Ajax Health. Together, Klein and Rohlen have created, backed and sold medtech companies that have generated billions.

Klein, formerly of New Enterprise Associates, now co-manages his own venture firm, Vensana Capital. He previously served on the board of directors of Cartiva (acquired), ChromaCode, CV Ingenuity (acquired), EPIX Therapeutics (acquired), FIRE1, GPB Scientific, Intact Vascular, Metavention, Personal Genome Diagnostics, PhaseBio Pharmaceuticals (IPO), Relievant Medsystems, Senseonics (IPO), Topera (acquired), Ulthera (acquired), Vertiflex (acquired), Vesper Medical and Vytro…

Read more
  • 0